Suppr超能文献

对于没有明显合并症的年轻低危 MDS 患者,异体干细胞移植中采用减低强度预处理可提高生存率。

Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities.

机构信息

Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul.

出版信息

Eur J Haematol. 2011 Dec;87(6):510-20. doi: 10.1111/j.1600-0609.2011.01697.x. Epub 2011 Oct 2.

Abstract

OBJECTIVE

The aim of this study was to determine the optimum conditioning intensity for allogeneic stem cell transplantation (SCT) in young (age ≤50), lower-risk (INT-1 by IPSS) Myelodysplastic syndrome (MDS) patients without significant comorbidities (hematopoietic cell transplantation-comorbidity index score ≤3).

METHODS

Transplant outcomes from 46 consecutive patients were retrospectively analyzed according to the conditioning intensity: reduced-intensity conditioning (RIC; n = 14), intensified RIC by adding low-dose total body irradiation (iRIC; n = 15), and myeloablative conditioning (MAC; n = 17).

RESULTS

After a median follow-up of 73.7 months, RIC had a better 4-yr overall survival (OS) (92.9%) compared with the iRIC (64.2%) or MAC (70.6%). Multivariate analysis showed that RIC was associated with improved OS compared with the MAC [relative risk (RR) of 0.08, P = 0.022] because of a lower transplant-related mortality (TRM) (RR, 0.08, P = 0.035). iRIC failed to show survival benefits over the MAC (RR of 0.77, P = 0.689) because of similarly high TRM (RR of 0.41, P = 0.480). Cumulative incidence of acute and chronic graft-versus-host disease (GVHD) after RIC was higher, but GVHD-specific survival was significantly better (RIC 100% vs. iRIC 45.7% vs. MAC, P = 0.018). Relapse rate was not different among the three groups, but in the RIC group, azacitidine was available and useful for inducing remission in two patients.

CONCLUSION

This study shows that RIC improved OS by directly lowering TRM and indirectly giving an additional chance for relapsed MDS in the era of hypomethylating treatment. RIC-SCT should be considered for relative healthy lower-risk MDS patients.

摘要

目的

本研究旨在确定无明显合并症(造血细胞移植合并症指数评分≤3)的年轻(年龄≤50 岁)、低危(国际预后评分系统 INT-1)骨髓增生异常综合征(MDS)患者进行异基因干细胞移植(SCT)的最佳预处理强度。

方法

根据预处理强度,回顾性分析了 46 例连续患者的移植结果:降低强度预处理(RIC;n=14)、通过添加低剂量全身照射强化 RIC(iRIC;n=15)和清髓性预处理(MAC;n=17)。

结果

中位随访 73.7 个月后,RIC 的 4 年总生存率(OS)(92.9%)明显优于 iRIC(64.2%)或 MAC(70.6%)。多变量分析显示,与 MAC 相比,RIC 与改善 OS 相关[相对风险(RR)为 0.08,P=0.022],因为移植相关死亡率(TRM)较低(RR,0.08,P=0.035)。由于 TRM 相似(RR,0.41,P=0.480),iRIC 未能显示优于 MAC 的生存获益(RR 为 0.77,P=0.689)。RIC 后急性和慢性移植物抗宿主病(GVHD)的累积发生率较高,但 GVHD 特异性生存率显著提高(RIC 为 100%,iRIC 为 45.7%,MAC 为 0.018)。三组的复发率无差异,但在 RIC 组,阿扎胞苷可用于诱导两名患者缓解,且有效。

结论

本研究表明,RIC 通过直接降低 TRM 和间接为低甲基化治疗时代复发的 MDS 提供额外机会来改善 OS。RIC-SCT 应考虑用于相对健康的低危 MDS 患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验